MXPA03005915A - Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c. - Google Patents
Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c.Info
- Publication number
- MXPA03005915A MXPA03005915A MXPA03005915A MXPA03005915A MXPA03005915A MX PA03005915 A MXPA03005915 A MX PA03005915A MX PA03005915 A MXPA03005915 A MX PA03005915A MX PA03005915 A MXPA03005915 A MX PA03005915A MX PA03005915 A MXPA03005915 A MX PA03005915A
- Authority
- MX
- Mexico
- Prior art keywords
- ht2b
- receptor ligands
- indole derivatives
- ht2c receptor
- ht2c
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0031724A GB0031724D0 (en) | 2000-12-27 | 2000-12-27 | Indole derivatives |
GB0119820A GB0119820D0 (en) | 2001-08-14 | 2001-08-14 | Indole derivatives |
PCT/EP2001/014781 WO2002051844A1 (en) | 2000-12-27 | 2001-12-14 | Indole derivatives and their use as 5-ht2b and 5-ht2c receptor ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03005915A true MXPA03005915A (es) | 2003-09-10 |
Family
ID=26245498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03005915A MXPA03005915A (es) | 2000-12-27 | 2001-12-14 | Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c. |
Country Status (16)
Country | Link |
---|---|
US (1) | US6610685B2 (es) |
EP (1) | EP1347979B1 (es) |
JP (1) | JP4094950B2 (es) |
KR (1) | KR100539143B1 (es) |
CN (1) | CN1250549C (es) |
AR (1) | AR035722A1 (es) |
AT (1) | ATE369368T1 (es) |
AU (1) | AU2002228007B2 (es) |
BR (1) | BR0116605A (es) |
CA (1) | CA2432085C (es) |
DE (1) | DE60129841T2 (es) |
ES (1) | ES2291374T3 (es) |
MX (1) | MXPA03005915A (es) |
PE (1) | PE20020911A1 (es) |
UY (1) | UY27097A1 (es) |
WO (1) | WO2002051844A1 (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4460450B2 (ja) | 2002-06-19 | 2010-05-12 | ビオヴィトルム・アクチボラゲット(プブリクト) | 新規化合物、その使用および製造法 |
US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
GB0314967D0 (en) * | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
EP1669350B1 (en) | 2003-09-22 | 2012-02-29 | Msd K.K. | Piperidine derivatives |
US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
EP1792629A4 (en) | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | PREVENTIVE / REMEDY AGENTS FOR INCONTINENCE OF STRESS AND SELECETING METHOD THEREOF |
CN101094689B (zh) | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
JP2008518917A (ja) | 2004-11-01 | 2008-06-05 | ワイス | Cns薬剤としての置換インドリジンおよび誘導体 |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
RU2417985C2 (ru) | 2005-05-30 | 2011-05-10 | Баниу Фармасьютикал Ко., Лтд. | Новые производные пиперидина |
CA2618112A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
BRPI0614649A2 (pt) | 2005-08-11 | 2011-04-12 | Amylin Pharmaceuticals Inc | polipeptìdeos hìbridos com propriedades selecionáveis |
EP1922336B1 (en) | 2005-08-11 | 2012-11-21 | Amylin Pharmaceuticals, LLC | Hybrid polypeptides with selectable properties |
AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
CA2621470A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
RU2008116844A (ru) | 2005-09-29 | 2009-11-10 | Мерк энд Ко., Инк. (US) | Ацилированные производные спиропиперидина как модуляторы рецептора меланокортина-4 |
WO2007048027A2 (en) | 2005-10-21 | 2007-04-26 | Novartis Ag | Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent |
EP1944301A4 (en) | 2005-10-27 | 2012-01-04 | Msd Kk | NEW BENZOXATHIIN DERIVATIVES |
NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
ATE448230T1 (de) | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
EP2742936A1 (en) | 2006-05-16 | 2014-06-18 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound and use thereof |
EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
AU2008206328B2 (en) | 2007-01-16 | 2013-10-31 | Ipintl, Llc | Novel composition for treating metabolic syndrome |
JP5319518B2 (ja) | 2007-04-02 | 2013-10-16 | Msd株式会社 | インドールジオン誘導体 |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
CN101772513B (zh) | 2007-06-04 | 2013-11-13 | 协同医药品公司 | 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂 |
EP2216023A4 (en) | 2007-11-15 | 2013-03-13 | Takeda Pharmaceutical | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF |
EP2264026A4 (en) | 2008-03-06 | 2012-03-28 | Msd Kk | ALKYLAMINOPYRIDINE DERIVATIVE |
JPWO2009119726A1 (ja) | 2008-03-28 | 2011-07-28 | Msd株式会社 | メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体 |
CA2666036C (en) | 2008-05-16 | 2017-09-12 | Chien-Hung Chen | Novel compositions and methods for treating hyperproliferative diseases |
EP2328910B1 (en) | 2008-06-04 | 2014-08-06 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
EP2319841A1 (en) | 2008-07-30 | 2011-05-11 | Msd K.K. | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
US8410284B2 (en) | 2008-10-22 | 2013-04-02 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
AU2009309037A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
US20110245209A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2510949A4 (en) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
EP2538784B1 (en) | 2010-02-25 | 2015-09-09 | Merck Sharp & Dohme Corp. | Benzimidazole derivatives useful anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
MX2015001500A (es) | 2012-08-02 | 2015-04-08 | Merck Sharp & Dohme | Compuestos antidiabeticos triciclicos. |
US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
CA2913737A1 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
BR112017003745A2 (pt) | 2014-08-29 | 2017-12-05 | Tes Pharma S R L | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico |
CN109952292A (zh) | 2016-10-14 | 2019-06-28 | Tes制药有限责任公司 | α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂 |
WO2019131902A1 (ja) | 2017-12-27 | 2019-07-04 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
AU2019385644A1 (en) | 2018-11-20 | 2021-06-03 | Tes Pharma S.R.L. | Inhibitors of α-Amino-β-carboxymuconic acid semialdehyde decarboxylase |
TW202045476A (zh) | 2019-02-13 | 2020-12-16 | 美商默沙東藥廠 | 5-烷基吡咯啶食慾素受體促效劑 |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
IL300610A (en) | 2020-08-18 | 2023-04-01 | Merck Sharp ַ& Dohme Llc | Bicycloheptane pyrrolidine compounds are orexin receptor agonists |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
TW334423B (en) * | 1993-10-22 | 1998-06-21 | Hoffmann La Roche | Tricyclic 1-aminoethylpyrrole-derivatives |
TW270114B (es) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
AU5343298A (en) | 1997-01-13 | 1998-08-03 | Yamanouchi Pharmaceutical Co., Ltd. | 5-ht2c receptor agonists and aminoalkylindazole derivatives |
US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
KR20010079636A (ko) | 1998-08-14 | 2001-08-22 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 라이페이즈 저해제 및 키토산을 포함하는 약학 조성물 |
DK1105122T3 (da) | 1998-08-14 | 2005-08-08 | Hoffmann La Roche | Pharmaceutical compositions containing lipase inhibitors |
GB9819035D0 (en) | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
IL143323A0 (en) * | 1998-12-17 | 2002-04-21 | American Home Prod | 2,3,4,4a-tetrahydro-1h-pyrazino (1,2-a) quinoxalin-5 (6h) one derivatives being 5ht2c agonists |
EP1132389A1 (en) * | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
-
2001
- 2001-12-14 DE DE60129841T patent/DE60129841T2/de not_active Expired - Lifetime
- 2001-12-14 JP JP2002552939A patent/JP4094950B2/ja not_active Expired - Fee Related
- 2001-12-14 US US10/017,978 patent/US6610685B2/en not_active Expired - Fee Related
- 2001-12-14 AT AT01989597T patent/ATE369368T1/de not_active IP Right Cessation
- 2001-12-14 WO PCT/EP2001/014781 patent/WO2002051844A1/en active IP Right Grant
- 2001-12-14 EP EP01989597A patent/EP1347979B1/en not_active Expired - Lifetime
- 2001-12-14 KR KR10-2003-7008679A patent/KR100539143B1/ko not_active IP Right Cessation
- 2001-12-14 ES ES01989597T patent/ES2291374T3/es not_active Expired - Lifetime
- 2001-12-14 CA CA002432085A patent/CA2432085C/en not_active Expired - Fee Related
- 2001-12-14 BR BR0116605-0A patent/BR0116605A/pt not_active IP Right Cessation
- 2001-12-14 AU AU2002228007A patent/AU2002228007B2/en not_active Ceased
- 2001-12-14 MX MXPA03005915A patent/MXPA03005915A/es active IP Right Grant
- 2001-12-14 CN CNB018213510A patent/CN1250549C/zh not_active Expired - Fee Related
- 2001-12-21 PE PE2001001298A patent/PE20020911A1/es not_active Application Discontinuation
- 2001-12-21 AR ARP010106000A patent/AR035722A1/es not_active Application Discontinuation
- 2001-12-26 UY UY27097A patent/UY27097A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20030063476A (ko) | 2003-07-28 |
EP1347979A1 (en) | 2003-10-01 |
DE60129841D1 (de) | 2007-09-20 |
CN1250549C (zh) | 2006-04-12 |
US6610685B2 (en) | 2003-08-26 |
AU2002228007B8 (en) | 2002-07-08 |
JP4094950B2 (ja) | 2008-06-04 |
ES2291374T3 (es) | 2008-03-01 |
EP1347979B1 (en) | 2007-08-08 |
WO2002051844A1 (en) | 2002-07-04 |
CA2432085C (en) | 2009-02-24 |
AU2002228007B2 (en) | 2007-06-21 |
UY27097A1 (es) | 2002-07-31 |
CN1483034A (zh) | 2004-03-17 |
ATE369368T1 (de) | 2007-08-15 |
KR100539143B1 (ko) | 2005-12-26 |
JP2004517852A (ja) | 2004-06-17 |
PE20020911A1 (es) | 2002-10-22 |
BR0116605A (pt) | 2003-09-30 |
DE60129841T2 (de) | 2008-04-17 |
AR035722A1 (es) | 2004-07-07 |
CA2432085A1 (en) | 2002-07-04 |
US20020160997A1 (en) | 2002-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03005915A (es) | Derivados de indol y su uso como ligandos receptores de 5-ht2b y 5-ht2c. | |
MXPA03003246A (es) | Derivados de indolina y su uso como ligandos del receptor 5-ht2. | |
MXPA03005648A (es) | Derivados de carbazol y su uso, como ligandos de receptor del neuropeptido y5. | |
AU5637199A (en) | Indoline derivatives as 5-ht2b and/or 5-ht2c receptor ligands | |
AU4667101A (en) | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands | |
PL353969A1 (en) | Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof as adenosine receptor ligands | |
HK1047743A1 (en) | New use and novel n-azabicyclo-amide derivatives. | |
HUP0400249A3 (en) | Pyridine derivatives as 5-ht receptor ligands and uses thereof | |
IL155634A0 (en) | 3-arylindole derivatives and their use as cb2 receptor agonists | |
MXPA02008801A (es) | Derivados de indol, proceso para la preparacion de los mismos y su uso. | |
MXPA02001508A (es) | Derivados de arilmetil-carbonilamino-tiazol y sus usos como agentes antitumorales. | |
AU2002217287A1 (en) | Benzo(f) isoindol derivatives and their use as ep4 receptor ligands | |
AU2001246671A1 (en) | Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands | |
GB0012934D0 (en) | Thermal tracer | |
MXPA03003039A (es) | Derivados de indola y bencimidazola como moduladores del receptor crf. | |
MXPA03004644A (es) | Derivados de fenilacetamdia-pirazol y su uso como agentes antitumorales. | |
HUP0203961A3 (en) | 3-phenoxy-1-phenyl acetylene derivatives and their use as herbicedes | |
IL151154A0 (en) | Indol-3-yl derivatives | |
ZA200207489B (en) | Apomorphine derivatives and methods for their use. | |
MXPA03000644A (es) | Nuevos derivados de indol y uso como medicamentos. | |
AU8664701A (en) | Oxindole derivatives | |
MXPA03004136A (es) | Derivados de pirimidina y su uso como ligandos del receptor de neuropeptido y (npy). | |
MXPA01012041A (es) | Derivados de indol. | |
AU2001259051A1 (en) | Piperidyindoles as serotonin receptor ligands | |
HK1049161A1 (en) | Indole derivatives. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |